New evidence surfaces to support cannabinoids as treatment for prostate cancer
It seems that there may be no end to the positive benefits of cannabis and its various components. A new study that was just published in the journal The Prostate provides evidence that cannabinoids could be a natural solution to a problem that affects one in every seven men – prostate cancer.
According to the study, “Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer.” Researchers based their findings after exploring the “anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.”
The researchers explained that “established prostate cancer cells (PC3, DU145, LNCaP) were treated with varying concentrations of WIN”, and that “Cell proliferation was determined by the MTS assay.” WIN’s potential to control cancer migration “was examined by the wound healing assay and the matrigel invasion essay.”
The study concluded that “WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner. The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.”
Obviously, more testing is needed and this study was conducted only on a small sample. However, given the positive results, it certainly is a strong indicator of the value of cannabinoids to fight not only arthritic pain and insomnia, but also severe ailments such as cancer.